Advertisement

Topics

Finn-Medi Research Company Profile

09:37 EDT 22nd September 2017 | BioPortfolio

Finn-Medi Research was established in 1995 and it is owned by Finnvera, the Hospital District of Pirkanmaa, the Finnish National Fund for Research and Development (SITRA), Finnish Red Cross, City of Tampere, Tampere University of Technology Foundation, and Tampere University Foundation. The company has 14 permanent employees and its projects involve more than 100 people annually. Finn-Medi Research implements some 100 projects per year. Our Turnover in 2004 was 2,4 M€. With its skilled staff and through its wide national and international connections to research institutions, financiers, corporations and other development companies, FinnMedi can offer a covering network and appropriate expertise to its customers' service

Location

Biokatu 12, 4 th floor
Tampere
33520
Finland

Contact

Phone: 358 3 3116 4023
Fax: 358 3 3116 4029
Email: info@finnmedi.fi


News Articles [320 Associated News Articles listed on BioPortfolio]

#Cannabis Stock News: Standard (TSX VENTURE: $SGH.V) to Acquire Medi-Can Health Solutions Ltd.

VANCOUVER, BRITISH COLUMBIA - September 1, 2017 (Investorideas.com Newswire) Standard Graphite Corp. (TSX VENTURE:SGH) (the "Company") is pleased to announce that it has entered into a share purchase ...

Melody Gersonde-Mickelson’s Newly Released “Finn Mouseson” is a Captivating Story of a Young Mouse That Sets Out On an Adventure of a Lifetime

(PRWEB) September 20, 2017 “Finn Mouseson”: follows the exciting story of a mouse as the need for adventure decides to tak...

MEDI+SIGN® Designated a ResponderSync® Partner at Rauland-Borg Corporation

Smithsburg, Maryland (PRWEB) September 07, 2017 MEDI+SIGN announces the recent designation of ResponderSync Partner by Rauland-Borg,...

Medi-Cal Programs: Being Required To Send Immediately Out-Of-Date Directory Is ‘Ridiculous’

California officials are being asked to review the requirement that massive, printed books be sent out to people who enroll for Medi-Cal. Outlets report on other Medicaid news out of South Carolina an...

Medi-Dose/EPS white paper touts potential of barcodes in healthcare

Medi-Dose/EPS, makers of solutions for preventing medication errors, have recently published a white paper, “Bar Codes and Bar Code Scanners for Unit Dose Medication In a Healthcare Setting.&rdq...

MEDI+SIGN Announces Dr. Thomas Dolan as New Advisory Board Member

MEDI+SIGN is proud to announce the esteemed Dr. Thomas Dolan as a new advisory board member to assist in the company’s healthcare communications and technology activities. Smithsburg, Maryland (PRWE...

MEDI+SIGN® Designated a ResponderSync® Partner at Rauland-Borg Corporation

MEDI+SIGN partners with Rauland-Borg to expand connectivity portfolio and to create the ideal communications solution for Rauland ResponderSync users Smithsburg, Maryland (PRWEB) September 07, 2017 M...

MEDI+SIGN Announces Harley Flack as New Advisory Board Member

MEDI+SIGN is honored to announce Harley Flack as a new Advisory Board member to assist in the company’s healthcare communications and technology endeavors. Smithsburg, Maryland (PRWEB) August 01, 20...

Drugs and Medications [132 Associated Drugs and Medications listed on BioPortfolio]

Denti-care denti-rinse [AR Medicom Inc]

Denti-Care Denti-Rinse 2 % Neutral Sodium Fluoride Oral Rinse Berry

Denti-care denti-rinse [AR Medicom Inc]

Denti-Care Denti-Rinse 2 % Neutral Sodium Fluoride Oral Rinse Mint

Denti-care denti-freeze [AR Medicom Inc]

Denti-Care Denti-Freeze Topical Anesthetic Gel Strawberry

Denti-care denti-freeze [AR Medicom Inc]

Denti-Care Denti-Freeze Topical Anesthetic Gel Raspberry

Mckesson medi-pak sterile [McKesson Medical-Surgical]

Drug Facts

PubMed Articles [1803 Associated PubMed Articles listed on BioPortfolio]

Suicide attempt in mental disorders (MeDi): Association with 5-HTT, IL-10 and TNF-alpha polymorphisms.

Mental disorders (MeDi) and suicide attempts (SA) are influenced by environmental and genetic factors. Genetic polymorphism studies have identified some candidate genes for suicidal behaviour in peopl...

Validation of Medi·Ca EC Method for AOAC Research Institute Performance Tested MethodsSM Certification (Certificate No. 031601).

A ready-made dry medium method for <em>Escherichia coli</em> and coliform count, the Medi•Ca EC method, wascompared with the most probable number (MPN) method using Brilliant Green Lacto...

Effects of ICOS+ T cell depletion via afucosylated monoclonal antibody MEDI-570 on pregnant cynomolgus monkeys and the developing offspring.

MEDI-570 is a fully human afucosylated monoclonal antibody (MAb) against Inducible T-cell costimulator (ICOS), highly expressed on CD4+ T follicular helper (TFH) cells. Effects of MEDI-570 were evalua...

The Impact of the Mediterranean Diet on the Cognitive Functioning of Healthy Older Adults: A Systematic Review and Meta-Analysis.

Evidence from epidemiologic studies suggests a relation between the Mediterranean diet (MeDi) and cognitive function, but results are inconsistent. Prior reviews have not provided pooled data from met...

Factors associated with Mediterranean diet adherence in Huntington's disease.

Little is known about the importance of the Mediterranean Diet (MeDi) and dietary intake as environmental neuroprotective factors in Huntington's disease (HD); so, we evaluated and analyzed the preval...

Clinical Trials [986 Associated Clinical Trials listed on BioPortfolio]

A Study of the Safety and Tolerability of MEDI-570 (Experimental Drug) in Systemic Lupus Erythematosus

The purpose of this study is to evaluate the safety and tolerability of MEDI-570 in adult subjects with moderately to severely active systemic lupus erythematosus (SLE).

Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)

The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-545 compared with placebo, over a dose escalation range of 0.3-30 mg/kg, i...

Study of MEDI 507 in the Treatment of Pediatric Patients

To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone marrow allograft recipients who have at least Grade II GvHD.

A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis

To compare disease activity, as measured by PASI score, of three MEDI-507 dosing (injection)regimens vs. placebo.

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

A Phase I studyto evaluate the safety and tolerability of escalating subcutaneous (SC) doses of MEDI-528 in to healthy adult volunteers.

Companies [1016 Associated Companies listed on BioPortfolio]

Finn-Medi Research

Finn-Medi Research was established in 1995 and it is owned by Finnvera, the Hospital District of Pirkanmaa, the Finnish National Fund for Research and Development (SITRA), Finnish Red Cross, City of T...

Histola Oy Ltd

Histola Ltd is established to provide a comprehensive range of histological techniques to meet each investigators needs. Our team is offering decades of combined experience in all phases of histopatho...

Medi-Span

Medi-Span is the leading provider of drug information for thousands of health care professionals worldwide. With more than 30 years experience, Medi-Span continues to offer author...

Joseph F. Finn, Jr., C.P.A.

Finn, Warnke & Gayton

More Information about "Finn-Medi Research" on BioPortfolio

We have published hundreds of Finn-Medi Research news stories on BioPortfolio along with dozens of Finn-Medi Research Clinical Trials and PubMed Articles about Finn-Medi Research for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Finn-Medi Research Companies in our database. You can also find out about relevant Finn-Medi Research Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record